Related Experiment Video
Updated: Dec 15, 2025
07:06
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
27.5K
Fecal microbiota transplantation for ulcerative colitis
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Chiba, Japan.
Immunological Medicine
|July 15, 2020
Summary
Fecal microbiota transplantation (FMT) shows promise for treating ulcerative colitis (UC) by restoring gut microbiota balance. Recent trials indicate FMT is more effective than control treatments for UC patients with dysbiosis.
Area of Science:
- Microbiome research
- Gastroenterology
- Immunology
Background:
- Gut microbiota dysbiosis is linked to various diseases, including gastrointestinal, metabolic, neurological, and autoimmune disorders.
- Ulcerative colitis (UC) is characterized by chronic gut inflammation and is associated with reduced gut microbial diversity and abundance.
- Fecal microbiota transplantation (FMT) is an emerging therapeutic strategy to correct dysbiosis.
Purpose of the Study:
- To evaluate the efficacy of FMT as a treatment for ulcerative colitis (UC).
- To assess the potential of FMT in restoring gut microbiota balance in UC patients.
Main Methods:
- Review of recent randomized controlled trials (RCTs) investigating FMT for UC.
- Analysis of clinical outcomes and efficacy compared to control treatments.
Main Results:
- Three out of four recent RCTs reported superior efficacy of FMT over control treatments for UC.
- Favorable effects of FMT in UC have been previously suggested in case reports and series.
Conclusions:
- FMT is a promising therapeutic option for ulcerative colitis (UC).
- Further research is needed to address challenges such as donor selection, administration methods, and optimal patient selection before FMT becomes a standard UC therapy.
Related Concept Videos
01:21Inflammatory Bowel Disease V: Surgical Management
339
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
339
01:29Drugs for Treatment of Ulcerative Colitis in IBD
346
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
346
01:50What is Monogastric Digestion?
74.7K
The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
74.7K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
366
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
366
01:17Drugs for Treatment of Diarrhea-Predominant IBS
506
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
506
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
731
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
731